结肠直肠癌腹膜转移防治临床研究

doi:10.16139/j.1007-9610.2021.01.002

摘要/Abstract

中图分类号:

关天培, 雷子颖, 崔书中. 结肠直肠癌腹膜转移防治临床研究[J]. 外科理论与实践, 2021, 26(01): 7-10.

Guan Tianpei, Lei ziying, Cui Shuzhong. Clinical study on prevention and treatment of peritoneal metastatic colorectal cancer[J]. Journal of Surgery Concepts & Practice, 2021, 26(01): 7-10.

图/表 1

参考文献 28

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[3]	Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database[J]. Lancet Oncol, 2016, 17(12):1709-1719. doi: S1470-2045(16)30500-9 pmid: 27743922
[4]	Hompes D, Tiek J, Wolthuis A, et al. HIPEC in T_4acolon cancer: a defendable treatment to improve oncologic outcome?[J]. Ann Oncol, 2012, 23(12):3123-3129. doi: S0923-7534(19)37483-6 pmid: 32018819
[5]	Segelman J, Granath F, Holm T, et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer[J]. Br J Surg, 2012, 99(5):699-705. doi: 10.1002/bjs.8679 pmid: 22287157
[6]	Razenberg LG, van Gestel YR, Creemers GJ, et al. Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands[J]. Eur J Surg Oncol, 2015, 41(4):466-471. doi: 10.1016/j.ejso.2015.01.018 pmid: 25680955
[7]	Lambert LA. Looking up: recent advances in understan-ding and treating peritoneal carcinomatosis[J]. CA Cancer J Clin, 2015, 65(4):284-298.
[8]	Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy[J]. J Clin Oncol, 2012, 30(20):2449-2456.
[9]	van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer[J]. N Engl J Med, 2018, 378(3):230-240.
[10]	Lei Z, Wang Y, Wang J, et al. Evaluation of cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for stageⅢ epithelial ovarian cancer[J]. JAMA Netw Open, 2020, 3(8):e2013940.
[11]	Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis[J]. J Clin Oncol, 2019, 37(23):2028-2040.
[12]	Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. NCCN guidelines insights: ovarian cancer, version 1.2019[J]. J Natl Compr Canc Netw, 2019, 17(8):896-909.
[13]	Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer[J]. J Clin Oncol, 2003, 21(20):3737-3743. pmid: 14551293
[14]	Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin[J]. J Clin Oncol, 2009, 27(5):681-685.
[15]	Franko J, Ibrahim Z, Gusani NJ, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis[J]. Cancer, 2010, 116(16):3756-3762. doi: 10.1002/cncr.25116 pmid: 20564081
[16]	Cashin PH, Graf W, Nygren P, et al. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study[J]. Eur J Surg Oncol, 2012, 38(6):509-515. doi: 10.1016/j.ejso.2012.03.001 pmid: 22475555
[17]	Quenet F, Elias D, Roca L, et al. A UNICANCER phase Ⅲ trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis. PRODIGE 7[J]. Eur J Surg Oncol, 2019, 45(2):e17.
[18]	Goere D, Glehen O, Quenet F, et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing co-lorectal peritoneal metastases(PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study[J]. Lancet Oncol, 2020, 21(9):1147-1154.
[19]	Nagourney RA, Evans S, Tran PH, et al. Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin[J]. Eur J Surg Oncol, 2020, S0748-7983(20):30789.
[20]	Bando H, Kagawa Y, Kato T, et al. A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer[J]. Br J Cancer, 2019, 120(10):982-986.
[21]	Schweiger T, Liebmann-Reindl S, Glueck O, et al. Mutational profile of colorectal cancer lung metastases and paired primary tumors by targeted next generation sequencing: implications on clinical outcome after surgery[J]. J Thorac Dis, 2018, 10(11):6147-6157. doi: 10.21037/jtd.2018.10.72 pmid: 30622786
[22]	Sammartino P, Sibio S, Biacchi D, et al. Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases[J]. Int J Colorectal Dis, 2014, 29(9):1081-1089. doi: 10.1007/s00384-014-1929-4 pmid: 24980687
[23]	Klaver C, Wisselink DD, Punt C, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial[J]. Lancet Gastroenterol Hepatol, 2019, 4(10):761-770.
[24]	雷子颖, 关天培, 罗嘉莉, 等. 局部进展期结直肠癌原发肿瘤切除术后5-8周行腹腔热灌注化疗的合理性[J]. 中华胃肠外科杂志, 2019, 22(12):1115-1116.
[25]	Becerra AZ, Aquina CT, Mohile SG, et al. Variation in delayed time to adjuvant chemotherapy and disease-specific survival in stage Ⅲ colon cancer patients[J]. Ann Surg Oncol, 2017, 24(6):1610-1617. doi: 10.1245/s10434-016-5622-4 pmid: 27738848
[26]	Elias D, Goere D, Dumont F, et al. Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases[J]. Eur J Cancer, 2014, 50(2):332-340. doi: 10.1016/j.ejca.2013.09.024 pmid: 24157254
[27]	蔡国响, 崔书中, 陈凛, 等. 腹腔热灌注化疗技术临床应用专家共识(2016版)[J]. 中华胃肠外科杂志, 2016, 19(2):121-125.
[28]	中国抗癌协会腹膜肿瘤专业委员会, 广东省抗癌协会肿瘤热疗专业委员会. 中国腹腔热灌注化疗技术临床应用专家共识(2019版)[J]. 中华医学杂志, 2020, 100(2):89-90.

结肠直肠癌腹膜转移防治临床研究

Clinical study on prevention and treatment of peritoneal metastatic colorectal cancer

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 28

相关文章 15

编辑推荐

Metrics

本文评价

[1]	孙祺, 黄文博, 何炳良, 刘畅, 徐宇航, 赵伟. 预防性腹腔热灌注化疗对局部进展期胃癌根治术后病人预后改善的有效性研究[J]. 外科理论与实践, 2023, 28(04): 366-370.
[2]	殷剑光, 宗雅萍, 沈晓卉, 赵敬坤, 陆爱国. 同时性多原发结肠直肠癌治疗与预后分析（附39例报告）[J]. 外科理论与实践, 2022, 27(06): 540-544.
[3]	包全, 邢宝才. 复杂双叶多发性结肠直肠癌肝转移外科治疗策略[J]. 外科理论与实践, 2022, 27(02): 128-130.
[4]	刘诗光, 赵敬坤, 陆爱国, 毛志海. 趋化因子CXCL5和程序性死亡配体 1在结肠直肠癌组织的表达与病人预后的关系[J]. 外科理论与实践, 2021, 26(06): 543-549.
[5]	张华, 陆炜, 杨承翌, 项明洁. 血清人衰老关键蛋白1检测对结肠直肠癌的诊断和预后价值[J]. 诊断学理论与实践, 2021, 20(05): 462-465.
[6]	杨盈赤, 宋建宁, 张忠涛. 中国腹腔镜结肠直肠手术的回顾与展望——基于手术病例登记研究和数据库建立的思考[J]. 外科理论与实践, 2021, 26(04): 277-280.
[7]	顾晋. 局部晚期结肠直肠癌治疗和联合脏器切除[J]. 外科理论与实践, 2021, 26(04): 290-296.
[8]	吴春晓, 龚杨明, 顾凯, 庞怡, 鲍萍萍, 王春芳, 施亮, 向詠梅, 窦剑明, 付晨, 施燕. 2016年上海市结肠直肠癌发病和死亡情况与2002—2016年间的变化趋势分析[J]. 外科理论与实践, 2021, 26(04): 325-335.
[9]	蔡三军. 结肠直肠癌诊治的思考[J]. 外科理论与实践, 2021, 26(04): 297-299.
[10]	张弢, 叶枫, 赵任. 结肠直肠癌的微创手术——在工具和价值间的不断平衡优化[J]. 外科理论与实践, 2021, 26(04): 300-304.
[11]	杨飖, 傅传刚. NOSES在结肠直肠癌手术中的应用现状与展望[J]. 外科理论与实践, 2021, 26(04): 305-311.
[12]	王常刚, 刘坤, 冯浩然, 蒋奕玫, 施毅卿, 陈献则, 宋子甲, 李军, 李佑, 蔡东莉, 赵任. 结肠直肠癌B7S1表达与免疫浸润的关系[J]. 外科理论与实践, 2021, 26(04): 336-342.
[13]	茅届齐, 徐多刚, 张米粒, 肖蕴誉, 明旭, 李雨哲, 曹灿, 于亮, 李继坤. 结肠直肠癌病人D-二聚体升高的研究[J]. 外科理论与实践, 2021, 26(04): 361-366.
[14]	朱正纲. 预防与治疗胃癌腹膜转移的若干关键问题[J]. 外科理论与实践, 2021, 26(01): 1-6.
[15]	姬忠贺, 李雁. 肿瘤细胞减灭术加腹腔热灌注化疗治疗胃癌腹膜转移的现状与前景[J]. 外科理论与实践, 2021, 26(01): 11-16.